Skip to main content

Table 1 Characteristics of the included patients

From: Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

Variable

anti-HBc positive, n (%)

anti-HBc negative, n (%)

P value

High-titer anti-HBc, n (%)

Low-titer anti-HBc, n (%)

P value

N

125

202

 

39

86

 

Age (years)

61.32 ± 8.01

60.61 ± 7.55

0.419

59.44 ± 7.469

62.17 ± 8.147

0.077

Gender

  

0.027*

  

0.154

 Male

85 (68)

112 (55.4)

 

23 (59.0)

62 (72.1)

 

 Female

40 (32)

90 (44.6)

 

16 (41.0)

24 (27.9)

 

Tumor site

 

0.72

  

1

 Colon

44 (35.2)

67 (33.2)

 

14 (35.9)

30 (34.9)

 

 Rectum

81 (64.8)

135 (66.8)

 

25 (64.1)

56 (65.1)

 

T stage

  

0.458

  

0.523

 T1

1 (0.8)

1 (0.5)

 

0 (0)

1 (1.2)

 

 T2

4 (3.2)

9 (4.5)

 

0 (0)

4 (4.7)

 

 T3

120 (96)

188 (93.1)

 

39 (100)

81 (94.2)

 

 T4

0 (0)

4 (2)

 

0 (0)

0 (0)

 

N stage

  

0.288

  

0.202

 N0

65 (52)

121 (59.9)

 

20 (51.3)

45 (52.3)

 

 N1

41 (32.8)

60 (29.7)

 

10 (25.6)

31 (36)

 

 N2

19 (15.2)

21 (10.4)

 

9 (23.1)

10 (11.6)

 

TNM stage

 

0.167

  

1

 II

65 (52)

122 (60.4)

 

20 (51.3)

45 (52.3)

 

 III

60 (48)

80 (39.6)

 

19 (48.7)

41 (47.7)

 

Histological types

 

0.447

  

0.092

 Adenocarcinoma

107 (85.6)

166 (82.2)

 

31 (79.5)

78 (90.7)

 

 Mucinous adenocarcinoma

18 (14.4)

36 (17.8)

 

8 (20.5)

8 (9.3)

 

Differentiation

 

0.652

  

0.253

 Well

6 (4.8)

10 (5)

 

1 (2.6)

5 (5.8)

 

 Moderately

87 (69.6)

152 (75.2)

 

29 (74.4)

58 (67.4)

 

 Poorly

19 (15.2)

22 (10.9)

 

3 (7.7)

16 (18.6)

 

 Not Available

13 (10.4)

18 (8.9)

 

6 (15.4)

7 (8.1)

 

Neoadjuvant therapy

1

  

0.501

 Yes

10 (8)

15 (7.4)

 

4 (10.3)

6 (7)

 

 No

115 (92)

187 (92.6)

 

35 (89.7)

80 (93)

 

Retrieved LN

 

0.173

  

0.663

 < 12

32 (25.6)

67 (33.2)

 

11 (28.2)

21 (24.4)

 

  ≥ 12

93 (74.4)

135 (66.8)

 

28 (71.8)

65 (75.6)

 

CEA (ng/ml)

 

0.909

  

0.332

  ≤ 5

70 (56)

111 (55)

 

19 (48.7)

51 (59.3)

 

 > 5

55 (44)

91 (45)

 

20 (51.3)

35 (40.7)

 

CA19-9(U/ml)

 

0.492

  

0.27

  ≤ 37

107 (85.6)

179 (88.6)

 

31 (79.5)

76 (88.4)

 

 > 37

18 (14.4)

23 (11.4)

 

8 (20.5)

10 (11.6)

 

ALT(U/L)

17.65 ± 9.50

19.86 ± 15.86

0.377

18.41 ± 9.85

17.31 ± 9.37

0.434

AST(U/L)

18.42 ± 6.70

19.01 ± 9.60

0.892

18.10 ± 6.12

18.56 ± 6.98

0.94

ALP(U/L)

83.90 ± 21.67

84.66 ± 24.98

0.86

82.56 ± 20.30

84.51 ± 22.34

0.643

PLT (1 × 109/L)

252.90 ± 67.98

250.91 ± 77.43

0.622

261.97 ± 67.56

84.51 ± 22.34

0.317

  1. Abbreviations: anti-HBc, antibodies to hepatitis B core antigen, CA19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase; PLT, platelets; LN, lymph node
  2. *Significant at P < 0.05
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us